Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Dermata Therapeutics Inc (DRMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.11% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.53M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 0.57 - 3.79 | Updated Date 07/13/2025 |
52 Weeks Range 0.57 - 3.79 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.9% | Return on Equity (TTM) -206.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5190805 | Price to Sales(TTM) - |
Enterprise Value -5190805 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 6378120 | Shares Floating 4154323 |
Shares Outstanding 6378120 | Shares Floating 4154323 | ||
Percent Insiders 18.16 | Percent Institutions 8.13 |
Upturn AI SWOT
Dermata Therapeutics Inc
Company Overview
History and Background
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing innovative, differentiated, and patent-protected therapeutics for the treatment of common skin diseases. Founded to address unmet needs in dermatology, the company has advanced multiple product candidates through clinical development.
Core Business Areas
- Medical Dermatology: Focuses on developing and commercializing therapies for common skin conditions like acne, rosacea, and seborrheic dermatitis.
Leadership and Structure
Dermata's leadership team consists of experienced executives in dermatology and pharmaceutical development. The organizational structure is typical of a clinical-stage biotech company, with teams dedicated to research, clinical development, regulatory affairs, and commercialization planning.
Top Products and Market Share
Key Offerings
- DRM01 (Seborrheic Dermatitis): DRM01 is a novel, investigational therapy for seborrheic dermatitis, currently in clinical development. No market share data is available as the product is not yet approved. Competitors include topical steroids, antifungals (e.g., ketoconazole), and calcineurin inhibitors.
- DRM02 (Acne): DRM02 is an investigational topical treatment for acne. No market share data is available as the product is not yet approved. Competitors include benzoyl peroxide, retinoids, and antibiotics.
Market Dynamics
Industry Overview
The medical dermatology market is characterized by a growing demand for effective treatments for common skin conditions, driven by increasing awareness, an aging population, and a desire for improved aesthetic outcomes. The market is competitive, with both established pharmaceutical companies and emerging biotech firms developing innovative therapies.
Positioning
Dermata is positioned as an innovator in medical dermatology, focused on developing differentiated products that address unmet needs. Their competitive advantage lies in their proprietary technologies and targeted approach to drug development.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the billions of dollars. Dermata is positioned to capture a portion of this TAM by targeting specific indications with innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced management team
- Promising clinical trial results
- Strong intellectual property protection
Weaknesses
- Reliance on successful clinical trials
- Limited financial resources as a clinical-stage company
- Dependence on regulatory approvals
- Lack of established commercial infrastructure
Opportunities
- Expansion into new dermatological indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial outcomes leading to regulatory approval
- Growing demand for innovative dermatology treatments
Threats
- Competition from established players
- Failure of clinical trials
- Regulatory setbacks
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- LEO
- VRX
- BMY
- LLY
Competitive Landscape
Dermata faces significant competition from established pharmaceutical companies with broader portfolios and greater resources. Dermata's advantage lies in its focused approach and potentially differentiated products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancements in clinical development and pipeline expansion.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates. Analyst estimates will be based on clinical trial data and market potential.
Recent Initiatives: Recent initiatives include advancing DRM01 and DRM02 through clinical trials and exploring potential partnerships.
Summary
Dermata Therapeutics is a clinical-stage company with promising dermatology assets, facing the typical risks of pharmaceutical development. Its success hinges on positive clinical trial results and subsequent regulatory approvals. While its focused approach is an advantage, limited resources and competition pose significant challenges. The company needs to continue executing its clinical strategy efficiently and seek strategic partnerships to enhance its commercialization potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be considered a recommendation to buy or sell any securities. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.